You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

December 2, 2024

Thailand’s Updated Guidelines on Kratom in Food and Herbal Products

Subscribe to Updates

Kratom (Mitragyna speciosa) was once listed as a prohibited substance under the Narcotics Act. Kratom was then removed from the narcotics list in 2021 and is now regulated under the Kratom Plant Act B.E. 2565 (2022), which allows the trading, use, import, and export of kratom. Furthermore, the Ministry of Public Health has allowed the use of kratom in food and drink, food supplements, and herbal products. Anyone who wishes to launch kratom food or herbal products must first obtain a product license from the Thai Food and Drug Administration (FDA).

On September 4, 2024, the Thai FDA announced guidelines specifically for powdered kratom leaves and kratom leaf extracts (using water or ethanol as solvents) as ingredients in food supplements. These guidelines aim to provide business operators with a clear framework for launching kratom-based food products in Thailand.

Key points from these guidelines include:

  • Raw material specifications and standards: Powdered kratom leaves and kratom leaf extracts must contain at least the prescribed amount of mitragynine (one of the primary active compounds in kratom) as a marker of quality. For example, mitragynine must account for at least 1% by mass for powdered kratom leaves.
  • Food supplement specification and standards: Food supplements containing powdered kratom leaves or kratom leaf extracts must not have a dosage of over 0.2 mg/day of mitragynine (including 7-hydroxymitraglynine, which may occur naturally), or 1 mg/day for food supplements containing kratom extracts that use water as a solvent. Addition of 7-hydroxymitraglynine to food supplements is prohibited.

    Mitragynine content in food supplement products must not exceed the specified dosage limit. Additionally, the food supplement product must be in a ready-to-eat form (e.g., liquid, gel, tablet, or capsule).

    If powdered kratom leaves or kratom leaf extracts are to be used as ingredients in food categories other than food supplements, a safety assessment must be conducted prior to their use, ensuring compliance with the necessary health and safety standards.

  • Manufacturing practices: The manufacturing locations of dietary supplements containing Kratom must comply with good manufacturing practice (GMP) standards, as specified in the annex to the Ministry of Public Health Announcement (No. 420) B.E. 2563 (2020) Re: Food Production Processes, Processing Equipment/Utensils and Storage Practices.
  • Labeling and warning statements: The labels of food supplements containing powdered kratom leaves or kratom leaf extracts must comply with the Notification of the Ministry of Public Health Re: Labeling and Food Supplement Products. The labels must also display the following warning statements:
    • Must not be consumed continuously for more than seven days.
    • Do not use this product in conjunction with other products containing kratom.
    • Must not be consumed with products containing alcohol.

    Additionally, there must be statements regarding prohibited usage for high-risk consumers. For example, products must not be used in patients with cardiovascular diseases, diabetes, or psychiatric disorders.

  • Approval process: Requests for approval of food supplement products containing powdered kratom leaves and kratom leaf extracts can be submitted online through the Thai FDA’s e-submission system. Submissions must include the product specifications, standards, and conditions of use in accordance with the established guidelines. Additionally, a laboratory report detailing the mitragynine content must be provided to the Thai FDA during the product registration process. If the product is imported, a certificate on the food standards of the manufacturing practices of the overseas manufacturer must be provided as part of the registration process.

Kratom as an Herbal Product
In addition to food products, kratom can also be approved as an herbal product under the Thai FDA’s Herbal Product Division. The requirements for registering kratom products as herbal products are distinct and include:

  • Herbal product specifications and standards: Kratom used in herbal products must adhere to strict quality and purity standards. This includes thorough testing for contaminants and verification of active ingredient concentrations. These stringent requirements ensure the safety and efficacy of kratom herbal products for consumers.

    The Herbal Product Division also provides guidelines for the registration of kratom leaf concentrates extracted using water and kratom leaf aqueous solutions. The guidelines specify that the amount of mitragynine must not exceed one milligram per day.

  • Manufacturing practices: Producers must adhere to good manufacturing practices (GMP) to ensure the consistency, safety, and efficacy of the herbal products. For importers, the manufacturing site is required to obtain GMP clearance verifying the standards of the overseas manufacturer, which must be equivalent or greater than the GMP standards in Thailand.
  • Labeling, leaflets, and packaging: Herbal products must have clear and informative labels that include dosage instructions, potential side effects, and contraindications. Kratom product labels and leaflets must have additional warnings or precautions as required to ensure the safety of the kratom usage. For instance, kratom products classified as herbal products for health promotion must display additional warning statements similar to the statements for food supplements mentioned above. Additionally, leaflets must contain contraindications to avoid safety issues, such as prohibiting the use of kratom products in people taking anticoagulants. These statements must comply with the guidelines issued by the Herbal Product Division.
  • Approval process: The approval process for herbal products involves submitting an application that includes product samples, safety data, and evidence of efficacy to the Herbal Product Division. The submitted documents must demonstrate that the products are safe for use and must provide evidence of the claimed health benefits.

Market Implications

The approval of kratom as a food or herbal product presents significant opportunities for both local and international producers. In Thailand, the number of approved kratom products remains relatively low, indicating substantial room for market expansion. Businesses can now legally cultivate, produce, and sell kratom if they adhere to the regulatory standards set by the Thai FDA. This regulatory clarity is anticipated to stimulate growth in the kratom market in terms of both domestic sales and export potential.

For further information on Thailand’s laws and regulations on kratom products, please contact Dr. Atthachai Homhuan at [email protected], Ravi Pinkoh at [email protected], or Sonatree Sehamontree at [email protected].

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
Read More
June 4, 2026
Indonesia’s Minister of Health has issued Decree No. HK.01.07/MENKES/301/2026 on the Affixation of Nutritional Labels and Health Information to Ready-to-Eat Processed Food Products. The decree came into force on April 14, 2026, and was issued to implement the Health Law and Minister of Health Regulation No. 3 of 2026 on Disease Control. The decree requires the inclusion of Nutri-Level labeling on the front-of-pack nutrition labeling (FOPNL) to indicate the product’s nutritional level based on the content of sugar, salt, and fat (“gula, garam dan lemak (GGL)”). Changes from 2024 Draft Regulation The Nutri-Level labeling was previously proposed in 2024 by the Indonesian FDA (BPOM) through a draft regulation concerning nutrition information. While the categories of Nutri-Level labeling remain the same in the issued decree, the content requirements of sugar, salt and fat in the decree are different from the earlier proposal introduced in the 2024 draft BPOM regulation. In addition, the decree has further specified that the content of fat in the Nutri-Level labeling is the content of saturated fat, not total fat as previously proposed in the 2024 draft. The decree requires Nutri-Level labeling to be implemented in beverage products, which is the same as previously proposed in the 2024 draft BPOM regulation. Other food products may gradually become subject to mandatory Nutri-Level labeling under future implementing regulations. Nutri-Level Labeling Food levels as shown by the Nutri-Level labeling are classified into four color-coded categories from A to D: Level A (lowest amount) in dark green Level B in light green Level C in yellow Level D (highest amount) in red The Nutri-Level labeling is represented by the following image. The requirements for each level for sugar, salt, and fat content, based on amounts per 100 milliliters of product in beverage form, are as follows. Nutri-Level information must be
Read More